Interleukin-6 inhibits regulatory t cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells

Journal of Immunotherapy

Volumn 35, Issue 4, 2012, Pages 337-343

  Lin, Guohe ^a,b   Wang, Jin ^a   Lao, Xiangming ^a   Wang, Jun ^a   Li, Lian ^c   Li, Shuhong ^a   Zhang, Jinye ^a   Dong, Yong ^b   Chang, Alfred E ^d   Li, Qiao ^d   Li, Shengping ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c Dongguan ShiLong People's Hospital   (China)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

cytokine induced killer cells; hepatocellular carcinoma; interleukin (IL) 6; regulatory T cells

Indexed keywords

CD45RO ANTIGEN; CHEMOKINE RECEPTOR CCR7; INTERLEUKIN 6; L SELECTIN;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CD3+ T LYMPHOCYTE; CD4 LYMPHOCYTE PERCENTAGE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE INDUCED KILLER CELL; CYTOTOXICITY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH17 CELL; TUMOR DIFFERENTIATION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-6; LIVER NEOPLASMS; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY;

EID: 84859882648     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318255ada3     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
2. Avila MA, Berasain C, Sangro B, et al. New therapies for hepatocellular carcinoma. Oncogene. 2006; 25: 3866-3884. (Pubitemid 43980482)
3. Ito F, Carr A, Svensson H, et al. Antitumor reactivity of anti- CD3/anti-CD28 bead-activated lymphoid cells: implications for cell therapy in a murine model. J Immunother. 2003; 26: 222-233. (Pubitemid 36686891)
4. Iuchi T, Teitz-Tennenbaum S, Huang J, et al. Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses. Cancer Res. 2008; 68: 4431-4441.
5. Li S, Yang J, Urban FA, et al. Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigenspecific tumor regression. Cancer Gene Ther. 2008; 15: 382-392. (Pubitemid 351693227)
6. Li Q, Teitz-Tennenbaum S, Donald EJ, et al. In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy. J Immunol. 2009; 183: 3195-3203.
7. Weng DS, Zhou J, Zhou QM, et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother. 2008; 31: 63-71. (Pubitemid 351619405)
8. Hui D, Qiang L, Jian W, et al. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis. 2009; 41: 36-41.
9. + regulatory T cells suppress NKT cell functions. Cancer Res. 2003; 63: 4516-4520. (Pubitemid 36951023)
10. + Tregulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol. 2006; 176: 1582-1587. (Pubitemid 43134302)
11. + cells in cytokineinduced killer cells derived from patients with pancreatic carcinoma. Cancer Immunol Immunother. 2004; 53: 1018-1026. (Pubitemid 39371746)
12. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccinemediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005; 115: 3623-3633. (Pubitemid 43121851)
13. Li H, Yu JP, Cao S, et al. CD4 +CD25+ regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients. J Clin Immunol. 2007; 27: 317-326. (Pubitemid 46790817)
14. + T cell-mediated suppression by dendritic cells. Science. 2003; 299: 1033-1036. (Pubitemid 36222922)
15. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007; 25: 2586-2593. (Pubitemid 47041232)
16. Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007; 132: 2328-2339. (Pubitemid 46890865)
17. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest. 2007; 117: 1167-1174. (Pubitemid 46718401)
18. + regulatory T cells by antigenprocessing dendritic cells. J Exp Med. 2003; 198: 235-247. (Pubitemid 37009740)
19. Attia P, Powell DJ Jr., Maker AV, et al. Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. J Immunother. 2006; 29: 208-214.
20. Banham AH, Powrie FM, Suri-Payer E. FOXP3+ regulatory T cells: current controversies and future perspectives. Eur J Immunol. 2006; 36: 2832-2836. (Pubitemid 44782555)
21. + T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother. 2005; 28: 120-128. (Pubitemid 40328198)
22. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004; 10: 909-915. (Pubitemid 39273730)
23. Holsti MA, Raulet DH. IL-6 and IL-1 synergize to stimulate IL-2 production and proliferation of peripheral T cells. J Immunol. 1989; 143: 2514-2519. (Pubitemid 19260057)
24. Schmidt-Wolf IG, Lefterova P, Mehta BA, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 1993; 21: 1673-1679. (Pubitemid 24223014)
25. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1993; 153: 1687-1696. (Pubitemid 24251113)
26. Zhang JP, Yan J, Xu J, et al. Increased intratumoral IL-17- producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 2009; 50: 980-989.
27. Canderan G, Dellabona P. T helper 17 T cells do good for cancer immunotherapy. Immunotherapy. 2010; 2: 21-24.
28. Martin-Orozco N, Muranski P, Chung Y, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009; 31: 787-798.
29. He D, Li H, Yusuf N, et al. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol. 2010; 184: 2281-2288.
30. Wang L, Yi T, Kortylewski M, et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009; 206: 1457-1464.
31. Maniati E, Soper R, Hagemann T. Up for mischief? IL-17/ Th17 in the tumour microenvironment. Oncogene. 2010; 29: 5653-5662.
32. Gery I, Gershon RK, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. I. The responding cell. J Exp Med. 1972; 136: 128-142.
33. Gery I, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. II. The cellular source of potentiating mediator(s). J Exp Med. 1972; 136: 143-155.
34. Schmidt-Wolf IG, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991; 174: 139-149.
35. Chen W, Yan W, Huang L. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol Immunother. 2008; 57: 517-530. (Pubitemid 351170535)
36. Ahonen CL, Wasiuk A, Fuse S, et al. Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood. 2008; 111: 3116-3125.
37. Zabala M, Lasarte JJ, Perret C, et al. Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. J Hepatol. 2007; 47: 807-815. (Pubitemid 350051122)
38. Litzinger MT, Fernando R, Curiel TJ, et al. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood. 2007; 110: 3192-3201. (Pubitemid 350106311)
39. Liu JY, Wu Y, Zhang XS, et al. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother. 2007; 56: 1597-1604 (Pubitemid 47094389)